Perseus Proteomics Inc
TSE:4882
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Perseus Proteomics Inc
Operating Income
Perseus Proteomics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Perseus Proteomics Inc
TSE:4882
|
Operating Income
-¥826.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Operating Income
-¥3.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-18%
|
|
|
GNI Group Ltd
TSE:2160
|
Operating Income
-¥2.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
PeptiDream Inc
TSE:4587
|
Operating Income
-¥5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Operating Income
-¥1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Operating Income
-¥2B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
Perseus Proteomics Inc
Glance View
Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
See Also
What is Perseus Proteomics Inc's Operating Income?
Operating Income
-826.4m
JPY
Based on the financial report for Mar 31, 2025, Perseus Proteomics Inc's Operating Income amounts to -826.4m JPY.
What is Perseus Proteomics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
0%
Over the last year, the Operating Income growth was 8%. The average annual Operating Income growth rates for Perseus Proteomics Inc have been -21% over the past three years .
